Clinical and Experimental Hepatology最新文献

{"title":"Profile of serum levels of TNF-α, IL-1β, IL-6, IL-8, IL-12, adiponectin, and vitamin D₃ in male Polish patients with acute alcoholic hepatitis and alcoholic cirrhosis.","authors":"Ryszard Tomasiuk, Magdalena Wiacek","doi":"10.5114/ceh.2025.153262","DOIUrl":"https://doi.org/10.5114/ceh.2025.153262","url":null,"abstract":"<p><strong>Aim of the study: </strong>Alcohol is one of the leading causes of liver hepatitis and liver cirrhosis. Both medical conditions are defined by a combination of specific symptoms whose interaction allows for a diagnosis with reasonable precision. This study aimed to differentiate between acute alcoholic hepatitis and alcoholic cirrhosis at the molecular level.</p><p><strong>Material and methods: </strong>This report analyzed changes in levels of vitamin D₃, tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, IL-8, IL-12, and adiponectin determined using a chemiluminescent microparticle immunoassay and Luminex xMap technology. The study population consisted of 42 male patients with acute alcoholic hepatitis and 50 male patients with alcoholic cirrhosis.</p><p><strong>Results: </strong>The result revealed a statistically significant difference in TNF-α, IL-8, and IL-12 between acute alcoholic hepatitis and alcoholic cirrhosis. It also revealed distinct correlation patterns that differentiate acute alcoholic hepatitis and alcoholic cirrhosis. A network of significant cross-correlations between the cytokines studied defines alcoholic cirrhosis.</p><p><strong>Conclusions: </strong>This report revealed that the studied medical conditions can be differentiated by specific levels of cytokines and by cross-correlation between cytokines.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"262-270"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting antiviral agents: expert position statement.","authors":"Jerzy Jaroszewicz, Marlena Broncel, Anna Piekarska, Filip M Szymanski, Krzysztof Tomasiewicz, Paweł Rajewski, Maciej Banach, Bartosz Hudzik, Mariusz Gąsior, Robert Flisiak, Robert Gil","doi":"10.5114/ceh.2025.154978","DOIUrl":"https://doi.org/10.5114/ceh.2025.154978","url":null,"abstract":"<p><p>The recently observed increase in cardiovascular disease incidence in patients with chronic hepatitis C has contributed to hepatitis C virus (HCV) being considered a new, non-classical risk factor. HCV infection may also lead to the development of metabolic disorders, which play an important role in the development of cardiovascular diseases. The notable impact of HCV on the development of obesity, insulin resistance, diabetes, lipid disorders and fatty liver has led to metabolic disorders in the course of HCV infection being referred to as metabolic-viral syndrome. On the other hand, modern treatment of HCV infection with direct-acting antiviral drugs is extremely effective and safe, while drug interactions are the main potential limitation. This article presents expert recommendations for the diagnosis and treatment of heart disease and lipid disorders in HCV-infected patients.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"205-218"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic heterogeneity in steatosis-driven liver injury among MASLD patients: Han Chinese vs. Caucasian.","authors":"Limin Lin, Junzhao Ye, Zhiyong Dong, Hong Deng, Yiyi Hu, Shiting Feng, Bing Liao, Xiaodong Zhuang, Bihui Zhong","doi":"10.5114/ceh.2025.154222","DOIUrl":"https://doi.org/10.5114/ceh.2025.154222","url":null,"abstract":"<p><strong>Aim of the study: </strong>Despite the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) worldwide, the ethnic differences in clinical features remain unknown. We aimed to compare steatosis-associated liver severity differences between Han Chinese vs. Caucasian patients with MASLD.</p><p><strong>Material and methods: </strong>This was a cross-sectional study comparing Han Chinese MASLD patients from four University-affiliated Medical Centers of fatty liver in south China from January 2015 to January 2023 and Caucasian MASLD patients from the UK Biobank database. All patients were measured for anthropometric parameters, biochemistry markers, metabolic tests and liver fat content (LFC) determined with the magnetic resonance imaging proton density fat fraction (MRI-PDFF).</p><p><strong>Results: </strong>Han Chinese MASLD patients (<i>n</i> = 620) had higher proportions of moderate and severe grades of steatosis than Caucasian MASLD patients (<i>n</i> = 829) (26.5% vs. 16.4%, <i>p</i> < 0.001). There was a linear positive correlation between serum alanine aminotransferase (ALT) levels and the average LFC in Han Chinese MASLD patients but not in Caucasian patients. Multivariate linear regression analysis demonstrated that such positive correlations between ALT levels and LFC remained (β' = 0.192, <i>p</i> < 0.001 in male patients; β' = 0.229, <i>p</i> < 0.001 in female patients). Furthermore, liver biopsies confirmed that Han Chinese patients showed higher liver histological severity - measured by SAF (Steatosis, Activity and Fibrosis) scores - as LFC increased (<i>r</i> = 0.632, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Han Chinese MASLD patients tended to suffer from higher risk of high liver fat content associated liver injuries than Caucasian patients, suggesting that higher hepatic lipotoxicity sensitivity compared to Caucasians might be one of the ethnic distinctions of Chinese populations.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"249-261"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-year outcomes under pemafibrate therapy in patients with metabolic dysfunction-associated steatotic liver disease: a long-term observational study.","authors":"Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Nikolaos Lazaridis, Hironori Yamamoto","doi":"10.5114/ceh.2025.154217","DOIUrl":"https://doi.org/10.5114/ceh.2025.154217","url":null,"abstract":"<p><strong>Aim of the study: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive disease that can cause cirrhosis and hepatocellular carcinoma. Although prevention strategies regarding MASLD progression are limited, pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has emerged as a credible candidate for MASLD therapy. There are no available data regarding three-year outcomes for patients treated with pemafibrate. The aim of this study was to assess three-year outcomes under pemafibrate therapy in patients with MASLD.</p><p><strong>Material and methods: </strong>This is a retrospective study reviewing the medical records of patients with MASLD treated with pemafibrate 0.2 mg daily for three years. Patients with diabetes were excluded. Laboratory parameters and adverse events were evaluated.</p><p><strong>Results: </strong>Forty patients with MASLD received pemafibrate therapy for three years. Alanine aminotransferase (ALT), a representative marker of hepatic inflammation, decreased significantly after one year and remained approximately 50% lower for three years. Regarding lipid profiles, triglyceride level decreased significantly at six months and remained lower. Mac-2 binding protein glycosylation isomer (M2BPGi), a marker of hepatic fibrosis, decreased at six months and was maintained for three years, although its levels fluctuated slightly. At three years, reduction of M2BPGi levels was positively correlated with amelioration of hepatic inflammation but not lipid profiles. There were no adverse events.</p><p><strong>Conclusions: </strong>Three-year outcomes of pemafibrate therapy are favorable in patients with MASLD. Long-term pemafibrate therapy has the potential to prevent progression of MASLD.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"242-248"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral health-related quality of life and oral function in patients with metabolic dysfunction associated steatotic liver disease.","authors":"Kouichi Miura, Naoshi Arai, Miki Ishikawa, Takako Yasuda, Nobue Wakabayashi, Aki Yamamoto, Yoshiyuki Mori, Kyoko Nakao, Hironori Yamamoto, Kazuhiko Kotani","doi":"10.5114/ceh.2025.154497","DOIUrl":"https://doi.org/10.5114/ceh.2025.154497","url":null,"abstract":"<p><strong>Aim of the study: </strong>Patients with metabolic dysfunction associated steatotic liver disease (MASLD) frequently experience periodontal diseases, but little is known about oral health-related quality of life (OHRQoL). Additionally, oral functions and the association between oral functions and MASLD remain unknown.</p><p><strong>Material and methods: </strong>The study included 19 MASLD patients and 26 control subjects. OHRQoL was assessed using the General Oral Health Assessment Index (GOHAI). Additionally, oral hygiene, periodontal conditions, and oral functions, including numbers of functional and dysfunctional teeth, were examined.</p><p><strong>Results: </strong>All MASLD patients were in the early stage of liver fibrosis and reported lower OHRQoL, particularly in physical components, including biting and chewing, and fluent speech. However, objective examinations revealed no significant differences in chewing and tongue pressure between MASLD and control subjects. Oral diadochokinesis also showed no significant difference. In contrast, MASLD patients exhibited fewer functional teeth, poorer oral hygiene, and more deteriorated periodontal condition. A reduced number of teeth was associated with MASLD, independent of periodontitis.</p><p><strong>Conclusions: </strong>MASLD patients reported lower OHRQoL and perceived impaired oral functions before actual functional loss occurred. A decreased number of functional teeth was associated with the presence of MASLD.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"232-241"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the removal of treatment barriers on the microelimination of chronic hepatitis C in Slovak prisons: experience from real-life settings.","authors":"Ivana Hockicková, Ján Hockicko, Peter Jarčuška, Sylvia Dražilová, František Lami, Patrícia D Lenártová, Pavol Mrážik, Adrián Gábor, Pavol Kristian","doi":"10.5114/ceh.2025.154078","DOIUrl":"https://doi.org/10.5114/ceh.2025.154078","url":null,"abstract":"<p><strong>Aim of the study: </strong>To evaluate the real-life experience of microelimination of chronic hepatitis C in Slovak prisons. We assessed the impact of removing treatment restrictions on the number of treated patients and the time from diagnosis to treatment initiation.</p><p><strong>Material and methods: </strong>A retrospective analysis was conducted on 205 incarcerated patients diagnosed with chronic hepatitis C between 2018 and 2024 in five prisons in Eastern Slovakia. We compared patient data before and after the removal of treatment indication restrictions.</p><p><strong>Results: </strong>Of the total of 205 patients, 94.1% (<i>n</i> = 193) were men. A history of intravenous drug use was reported by 93.7% of patients. Liver fibrosis stage F0-F1 had been confirmed in 74.9% and liver cirrhosis in 5.8% of patients. Additionally, liver cirrhosis was significantly associated with older age (<i>p</i> < 0.0005). The most common HCV genotypes were 3a (30.7%), 1a (23.4%) and 1b (21.5%). Following the complete removal of treatment restrictions in March 2024, the number of treated patients in 2024 increased more than threefold compared to 2023 and fourfold compared to the previous annual average. The time from diagnosis to treatment initiation was significantly reduced from 325 days to 91 days (<i>p</i> < 0.0005). Among treated patients, 98.2% achieved an end-of-treatment response (ETR), and 98.4% achieved a sustained virological response (SVR).</p><p><strong>Conclusions: </strong>The removal of treatment restrictions significantly improved access to therapy for incarcerated patients with HCV. Prisons provide a controlled setting for microelimination efforts, and expanding treatment in this population could contribute to broader national HCV elimination goals.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"271-278"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does thyroid function disorder play a vital role in the pathogenesis of neonatal cholestasis?","authors":"Salma Abdel Megeed Nagi, Mai Ibrahim Elashmawy, Mohamed Zaeim Hafez Ahmed, Mahmoud Ahmad Mohammed Azab, Ashraf AbdelAty Elshenawy Emara, Osama Mohammad Mohammad Abdelhay, Mohamed AbdelAziz Doma, Ahmad Mohamed Mohamed Awad, Ahmed Mohammed Saba, Tarek Shikhon, Hesham Abdelrahman Mahmoud Ahmed, Ahmed Mohamed Gad Allah, Marwa Fekry Hassan, Shymaa Sobhy Menshawy Khalifa","doi":"10.5114/ceh.2025.154503","DOIUrl":"https://doi.org/10.5114/ceh.2025.154503","url":null,"abstract":"<p><strong>Introduction: </strong>Neonatal cholestasis is a syndrome characterized by decreased bile flow in infants and has several underlying causes, including genetic and metabolic diseases. Thyroid dysfunction may contribute to the pathophysiology of cholestasis, although it is not often acknowledged as a major cause. Further research into this possible connection is necessary because studies have linked thyroid conditions, including hyperthyroidism and euthyroid sick syndrome, to liver damage in newborns. This study aimed to evaluate the thyroid function in infants with neonatal cholestasis and determine whether it has a role in the diagnosis of other causes of neonatal cholestasis.</p><p><strong>Material and methods: </strong>The study included 100 infants with neonatal cholestasis of different causes (50 infants with biliary atresia [BA] and 50 infants with other causes of neonatal cholestasis other than BA) attending the National Liver Institute, Menoufia University, between July 2024 and January 2025. The infants were evaluated for serum free triiodothyronine (T3), free tetraiodothyronine (T4), and thyroid-stimulating hormone (TSH).</p><p><strong>Results: </strong>T3 was significantly higher in the non-BA group (3.97 ±0.45) than the BA group (<i>p</i> < 0.0001), while T4 and TSH did not significantly differ among the studied patients (<i>p</i> ≥ 0.05).</p><p><strong>Conclusions: </strong>The results demonstrated significant differences in T3 levels, with higher levels observed in the non-BA group, while T4 and TSH showed no significant differences between the two groups. These findings suggest that thyroid dysfunction may be associated with neonatal cholestasis, particularly in conditions other than BA.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"289-299"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steatotic liver disease and chronic viral hepatitis.","authors":"Jakub Janczura, Alessandra Mangia, Krystyna Dobrowolska, Michał Brzdęk, Kinga Brzdęk, Małgorzata Wajdowicz, Iwona Gorczyca-Głowacka, Piotr M Stępień, Dorota Zarębska-Michaluk","doi":"10.5114/ceh.2025.154220","DOIUrl":"https://doi.org/10.5114/ceh.2025.154220","url":null,"abstract":"<p><p>Steatotic liver disease (SLD) is a condition characterized by excessive fat accumulation within hepatocytes. In recent years, the nomenclature and diagnostic framework of the disease have evolved and the term SLD has replaced the previous fatty liver disease classification. This change reflects a more inclusive understanding of the metabolic drivers of the disease and its strong association with systemic conditions. With the rising global prevalence of metabolic disorders, the burden of SLD has increased significantly, making it the leading cause of chronic liver disease worldwide. While many cases of SLD remain non-progressive, metabolic dysfunction associated steatohepatitis (MASH) may advance to fibrosis, cirrhosis, or hepatocellular carcinoma. The risk of disease progression may be greater when liver steatosis coexists with other hepatic insults, particularly chronic infections with hepatitis B virus or hepatitis C virus. This review explores the prevalence, interactions, and therapeutic implications of SLD in patients with chronic viral hepatitis.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"219-227"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of acute CMV coinfection on the course of EBV hepatitis in children.","authors":"Magdalena Rutkowska, Maria Pokorska-Śpiewak","doi":"10.5114/ceh.2025.154284","DOIUrl":"https://doi.org/10.5114/ceh.2025.154284","url":null,"abstract":"<p><strong>Aim of the study: </strong>Hepatitis occurs in 50-90% of patients hospitalized with primary Epstein-Barr virus (EBV) infection. Dual serological positivity for EBV and cytomegalovirus (CMV) may occur. Our retrospective study aimed to compare the clinical course of hepatitis between children with EBV monoinfection (Group 1) and those with EBV and CMV dual positivity (Group 2).</p><p><strong>Material and methods: </strong>In total, 244 patients were recruited. Eighty (32.79%) of them belonged to Group 2. The diagnosis of EBV and CMV infection was confirmed by positive viral capsid antigen (VCA) antibody testing and serum CMV IgM antibodies.</p><p><strong>Results: </strong>Clinical symptoms suggesting cholestasis occurred significantly more often in Group 2: nausea or vomiting in 35 (43.21%) vs. 45 (27.44%) in Group 1, <i>p</i> = 0.010 (OR = 2.01 [95% CI: 1.15-3.51]); abdominal pain in 37 (45.67%) vs. 52 (31.71%), <i>p</i> = 0.042 (OR = 1.81 [95% CI: 1.05-3.13]); dark urine in 12 (14.81%) vs. 8 (4.88%), <i>p</i> = 0.006 (OR = 3.39 [95% CI: 1.33-8.67]). The alanine aminotransferase (ALT) activity was higher in Group 2 during the first week of the disease, although the difference was not statistically significant (<i>p</i> = 0.083). Aspartate aminotransferase (AST) activity was significantly higher in Group 2 only in the first week of the disease (<i>p</i> = 0.023). Abnormal abdominal ultrasound results occurred more often in Group 2: 100% of patients vs. 66.46% in Group 1 (<i>p</i> = 0.045).</p><p><strong>Conclusions: </strong>In Group 2, we observed more pronounced clinical symptoms of hepatitis and more frequently abnormal ultrasound images of the liver and bile ducts.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"279-288"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implantation of nasobiliary drainage in treatment of severe episodes of benign recurrent intrahepatic cholestasis (BRIC) in pediatric patients.","authors":"Maciej Dądalski, Tetiana Wojciechowska, Joanna Ryżko, Magda Naorniakowska, Joanna Cielecka-Kuszyk, Elżbieta Ciara, Małgorzata Sawilska-Tańska, Joanna Pawłowska","doi":"10.5114/ceh.2025.153806","DOIUrl":"https://doi.org/10.5114/ceh.2025.153806","url":null,"abstract":"<p><p>Benign recurrent intrahepatic cholestasis (BRIC) is a rare genetic disorder characterized by episodes of intrahepatic cholestasis with varying durations and spontaneous resolutions. This article presents the use of nasobiliary drainage (NBD) in inducing remission of BRIC in our patients. We also analyze recent studies, case reports, and systematic reviews on the topic to provide an overview of the efficacy and safety of NBD in the management of BRIC. The paper is a review of a rarely (especially in children) used technique in therapy of acute episode of BRIC with a short presentation of a small series of patients in whom such a technique was applied in a single center. Our findings suggest that NBD could be a promising and effective approach for inducing remission in BRIC patients, warranting further research and larger clinical trials to better understand its long-term impact.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 3","pages":"228-231"},"PeriodicalIF":1.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13097282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}